Kleine Levin Syndrome

Kleine Levin syndrome is a rare, relapsing remitting neurological disorder. It is characterised by recurrent, discrete episodes of severe hypersomnia (excessive, prolonged sleep) with cognitive and behavioural features and, in a substantial proportion of patients, hyperphagia and hypersexuality.

It occurs predominantly in adolescent males.

A complete return to normal baseline functioning between episodes is an essential, defining feature. It distinguishes this condition from other causes of recurrent or persistent hypersomnia.

The underlying pathophysiology remains incompletely understood, despite recognised associations with preceding infection or other physiological stressors in a proportion of cases.

Pathophysiology

• The precise mechanism remains incompletely understood. Proposed contributing factors include autoimmune or inflammatory dysfunction affecting hypothalamic and thalamic regions involved in sleep wake regulation.
• Episode onset has a recognised, though inconsistent, association with a preceding infective illness, sleep deprivation, alcohol consumption, or other physiological stressor in a proportion of affected individuals. This suggests a potential triggering role in susceptible individuals, though the predisposing factors determining susceptibility remain poorly defined.
• The characteristic complete return to normal neurological and cognitive functioning between discrete episodes is a defining and diagnostically essential feature. It contrasts clearly with the persistent or progressive course typical of most other significant neurological conditions producing hypersomnia or cognitive change.

• The core defining feature is recurrent, discrete episodes of severe hypersomnia. The affected individual sleeps for the great majority of each day (often eighteen to twenty hours or more), waking only briefly for essential functions.
• Episodes typically last from several days to a few weeks before spontaneous resolution.
• During episodes, when briefly awake, patients characteristically show cognitive impairment (confusion, slowed thinking, impaired concentration) and behavioural change (irritability, apathy, a dreamlike or derealised subjective state frequently described by affected patients).
• In a substantial proportion, hyperphagia (excessive eating, sometimes with altered food preferences) and hypersexuality (increased sexual drive or disinhibited sexual behaviour or comments) are present. Together these contribute to the distinctive clinical picture.
• Between episodes, patients return completely to their normal baseline level of functioning, cognition and behaviour, without any persistent deficit. This is the essential distinguishing feature from other, more serious neurological conditions in the differential diagnosis of recurrent altered consciousness or behavioural change.
• The condition predominantly affects adolescent males, typically with onset in the second decade of life.
• Episodes generally recur at irregular intervals over subsequent months to years. Frequency typically, though not universally, reduces gradually, with eventual spontaneous resolution over time, often by early adulthood. The long term natural history is generally favourable, though variable and unpredictable.

• Diagnosis is predominantly clinical, based on the characteristic recurrent, discrete pattern of severe hypersomnia with associated cognitive and behavioural features. Confirm complete return to normal baseline functioning between episodes. Structured diagnostic criteria incorporating these features support confident diagnosis.
• Full investigation to exclude alternative causes of recurrent hypersomnia and behavioural change is essential before this diagnosis is confidently accepted.
• Magnetic resonance imaging of the brain is generally normal in Kleine Levin syndrome, supporting exclusion of a structural cause.
• Electroencephalography may show non specific slowing during an active episode. It does not show the epileptiform features that would suggest an alternative seizure related diagnosis.
• Where clinically relevant, use metabolic and toxicological screening to exclude alternative causes of episodic altered consciousness and behaviour.
• Polysomnography, where performed during an active episode, confirms genuine, physiological hypersomnia with increased total sleep time. It is not required for routine diagnosis given the characteristic, recognisable clinical pattern in the appropriate demographic and clinical context.
• The differential diagnosis includes primary psychiatric conditions, other causes of recurrent hypersomnia, and an underlying mood disorder with episodic hypersomnic features.
• Primary psychiatric conditions are relevant given the behavioural and mood related features. However, the pattern of discrete, self limiting episodes with complete interepisode recovery is atypical for most of them.
• An underlying mood disorder is particularly important to exclude, given differing management implications. Careful longitudinal assessment and characterisation of the episodic pattern generally allows confident distinction from these alternative diagnoses over time.

• There is no established, consistently effective disease modifying or preventive treatment for Kleine Levin syndrome. Management is predominantly supportive during acute episodes, given the generally self limiting nature of individual episodes and the characteristic, complete interepisode recovery.
• During an acute episode, supportive care focuses on safety (given the significantly impaired cognition and judgement), adequate hydration and nutrition, and supervision given the potential for behavioural disinhibition.
• Hydration and nutrition can be challenging, because the profound hypersomnia limits the periods of wakefulness available for eating and drinking.
• Hospital admission is occasionally required for severe episodes with significant difficulty maintaining hydration and nutrition, or where safety concerns warrant closer supervision than can be provided at home.
• Lithium has shown some evidence of benefit in reducing the frequency and severity of subsequent episodes in some case series and small studies. Consider it, particularly for patients with frequent, severe, significantly disruptive episodes, under specialist neurology or sleep medicine guidance.
• Robust, controlled trial evidence supporting routine use of lithium remains limited given the rarity of this condition.
• Stimulant medications have been trialled for symptomatic hypersomnia management during episodes. Evidence for consistent benefit is limited, and their use requires careful individual consideration given the potential for exacerbating the behavioural and mood related features in some patients.
• Patient and family education is an essential and often the most valuable component of management. It covers the generally benign, self limiting nature of individual episodes and the favourable, though variable, long term natural history with typical gradual resolution over subsequent years.
• Provide practical planning and support for managing the significant disruption to education, work and family life that recurrent episodes can cause.
• Ongoing specialist neurology or sleep medicine follow up provides longitudinal support and monitoring of episode pattern and frequency over time.
• Reassess for alternative diagnoses should the clinical pattern evolve atypically. Persistent, rather than complete, interepisode recovery, or a clearly progressive rather than static or improving overall course, would warrant reconsideration of the diagnosis and further evaluation for an alternative underlying condition.